-
New
Net Present Value Model: Terns Pharmaceuticals Inc’s TERN-501
Empower your strategies with our Net Present Value Model: Terns Pharmaceuticals Inc's TERN-501 report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
New
Net Present Value Model: Terns Pharmaceuticals Inc’s TERN-501
Empower your strategies with our Net Present Value Model: Terns Pharmaceuticals Inc's TERN-501 report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TERN-501 in Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TERN-501 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TERN-501 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Drug Details: TERN-501 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TERN-601 in Obesity
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TERN-601 in Obesity report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TERN-601 in Obesity Drug Details: TERN-601 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Insulin Human in Type 1 Diabetes (Juvenile Diabetes)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Insulin Human in Type 1 Diabetes (Juvenile Diabetes) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Insulin Human in Type 1 Diabetes (Juvenile Diabetes)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TERN-101 in Non-Alcoholic Steatohepatitis (NASH)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TERN-101 in Non-Alcoholic Steatohepatitis (NASH) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.TERN-101 in Non-Alcoholic Steatohepatitis (NASH)Drug Details:TERN-101 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TERN-501 in Non-Alcoholic Steatohepatitis (NASH)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TERN-501 in Non-Alcoholic Steatohepatitis (NASH) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.TERN-501 in Non-Alcoholic Steatohepatitis (NASH)Drug Details:TERN-501 is under development for the treatment...
-
Product Insights
NewNet Present Value Model: Opthea Ltd’s Sozinibercept
Empower your strategies with our Net Present Value Model: Opthea Ltd's Sozinibercept report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Drugs In Development, 2023
Global Markets Direct’s, ‘Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Drugs In Development, 2023’, provides an overview of the Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – OCX-063 in Proliferative Vitreoretinopathy (PVR)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - OCX-063 in Proliferative Vitreoretinopathy (PVR) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. OCX-063 in Proliferative Vitreoretinopathy (PVR) Drug Details: OCX-063 is under development...